Novo Nordisk A/S (NVO)
45.33
-0.28
(-0.61%)
USD |
NYSE |
Aug 31, 16:00
45.34
+0.01
(+0.02%)
After-Hours: 19:22
Novo Nordisk Total Long Term Debt (Quarterly) : 18.63B for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.63B |
| March 31, 2026 | 18.38B |
| December 31, 2025 | 18.91B |
| September 30, 2025 | 14.04B |
| June 30, 2025 | 13.74B |
| March 31, 2025 | 13.94B |
| December 31, 2024 | 12.64B |
| September 30, 2024 | 7.703B |
| June 30, 2024 | 7.417B |
| March 31, 2024 | 2.427B |
| December 31, 2023 | 3.216B |
| September 30, 2023 | 2.829B |
| June 30, 2023 | 2.845B |
| March 31, 2023 | 3.539B |
| December 31, 2022 | 3.632B |
| September 30, 2022 | 3.180B |
| June 30, 2022 | 3.399B |
| March 31, 2022 | 3.603B |
| December 31, 2021 | 1.982B |
| September 30, 2021 | 1.932B |
| June 30, 2021 | 1.988B |
| March 31, 2021 | 447.54M |
| December 31, 2020 | 476.21M |
| September 30, 2020 | 415.27M |
| June 30, 2020 | 412.15M |
| Date | Value |
|---|---|
| March 31, 2020 | 421.42M |
| December 31, 2019 | 452.01M |
| September 30, 2019 | 427.39M |
| June 30, 2019 | 454.23M |
| March 31, 2019 | 481.90M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AstraZeneca PLC | 30.91B |
| Johnson & Johnson | 37.34B |
| Eli Lilly & Co. | 49.62B |
| Merck & Co., Inc. | 51.08B |
| Novartis AG | 39.43B |